PASG (Passage Bio) 3-Year RORE % : -29.97% (As of Mar. 2026)


PASG Passage Bio Inc PASG
30 GF Score
Price $4.63
! 2 Warning Signs
View Full Analysis

What is Passage Bio 3-Year RORE %?

Passage Bio PASG +2.18% 30 3-Year RORE % is -29.97 as of Mar. 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,293 Biotechnology companies, Passage Bio ranks worse than 69.37% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Passage Bio's 3-Year RORE % for the quarter that ended in Mar. 2026 was -29.97%.

The industry rank for Passage Bio's 3-Year RORE % or its related term are showing as below:

PASG's 3-Year RORE % is ranked worse than
69.37% of 1293 companies
in the Biotechnology industry
Industry Median: -11.55 vs PASG: -29.97

Passage Bio  (NAS:PASG) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Passage Bio 3-Year RORE % Related Terms


Passage Bio 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Passage Bio's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Passage Bio 3-Year RORE % Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial 21.70 -6.44 -20.66 -26.52 -31.37

Passage Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.37 -26.81 -34.05 -31.37 -29.97

PASG vs CTXR, HIND, GTBP: 3-Year RORE % Comparison

For the Biotechnology subindustry, Passage Bio's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Passage Bio 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Passage Bio's 3-Year RORE % falls into.


PASG
30GF Score
Passage Bio Inc PASG
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio 3-Year RORE % Calculation

Passage Bio's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -11.85--30.6 )/( -62.56-0 )
=18.75/-62.56
=-29.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -29.97 mean?
Passage Bio (PASG) has a 3-Year RORE % of -29.97 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Passage Bio and its competitors. According to the industry distribution chart, Passage Bio ranks #897 out of 1293 companies in the Biotechnology industry, placing it in the top 69.4%.
Is Passage Bio's 3-Year RORE % too high?
Passage Bio's current 3-Year RORE % is -29.97. Based on the distribution chart, Passage Bio ranks #897 out of 1293 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's 3-Year RORE % compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #897 out of 1293 companies for 3-Year RORE %. This places Passage Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Passage Bio and its competitors. Passage Bio's current 3-Year RORE % is -29.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current 3-Year RORE % of -29.97. The current 3-Year RORE % is -29.97. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Passage Bio (PASG), the current 3-Year RORE % is -29.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price